The aim of this double-blind, double-dummy, parallel group study was to compare the effects of delaprilmanidipine combination vs a irbesartan-hydrochlorothiazide combination on plasma tissue plasminogen activator (t-PA) and plasmogen activator inhibitor type I (PAI-l) activities in hypertensive patients with type II diabetes mellitus. After a 4-week run-in placebo period, 80 patients (37 male and 43 female), aged 41-65 years, were randomly allocated to an 8-week treatment with delapril 30 mg once daily or irbesartan 150 mg once daily. Thereafter, manidipine l0 mg once daily was added to delapril treatment and hydrochlorothiazide 12.5 mg to irbesartan treatment for a further 8 weeks. Blood pressure (BP), plasma t-PA and PAI-l activities were evaluated at the end of the run-in period, after 4-week monotherapy treatments, and at the end of the combination treatment periods. Both combination treatments, delapril-manidipine and irbesartan-hydrochlorothiazide, produced a greater reduction in systolic BP/diastolic BP (SBP/DBP) values (À27.6/21.8 mmHg and À26.4/20.2 mmHg, respectively) than the respective monotherapies (À15.2/ 11.7 mmHg with delapril and À16.3/11.3 mmHg with irbesartan). Delapril monotherapy significantly decreased plasma PAI-l activity (À10.4 IU/mI; Po0.05). The addition of manidipine produced a significant increase in t-PA activity ( þ 0.27 IU/mI); Po0.05). Irbesartan monotherapy did not significantly affect the fibrinolytic balance, whereas the addition of hydrochlorothiazide worsened it, producing a significant increase in PAI-l activity ( þ 9.5 IU/ml; Po0.05). In hypertensive patients with type II diabetes mellitus, the combination delapril-manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan-hydrochlorothiazide may worsen it.
Introduction
According to the most recent guidelines of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) and the ESH-ESC Guidelines Committee, 1,2 the blood pressure (BP) goal to achieve with pharmacological therapies is below 140/90 mmHg. This goal is even lower (below 130/80 mmHg) in patients with a high cardiovascular risk, such as patients with diabetes mellitus. 1, 2 Most diabetic patients require combination therapy to achieve these more aggressive BP targets. [3] [4] [5] No significative differences in antihypertensive efficacy have been observed with a different combination of antihypertensive drugs. However, some combinations can be found to be more beneficial than one would expect from the only reduction of BP, as far as target organ damage is concerned. Inclusion of agents that target the renin-angiotensin system (RAS) may have particular benefits in reducing renal and cardiovascular risk in hypertensive patients with diabetes, and evidences suggest that these benefits may be due to both BP-dependent and-independent mechanisms. 1, 2, 6 The choice of the antihypertensive agents to associate should also take into account their metabolic profile, which should be beneficial or at least neutral, as well as their effect on the fibrinolytic system. This system, which is primarily regulated by the tissue plasminogen activator (t-PA) and its physiologically most important inhibitor, plasminogen activator inhibitor type l (PAI-l), is of crucial importance in the pathogenesis of intravascular thrombosis. 7, 8 Fibrinolytic activity tends to be reduced in hypertensive subjects 9, 10 as well as in type II diabetic patients 11, 12 with an increased risk of atherosclerosis and relative complications. Therefore, antihypertensive therapy should be aimed at counteracting this effect or, at least, not adversely affecting it. Scarce and controversial data can be found in the literature referring to different antihypertensive drugs and their effects on the fibrinolytic system. 13 Variable effects have been reported for diuretics 14, 15 and b-blockers, 16, 17 whereas Ca-antagonists seem to be associated with an increase in plasma t-PA activity. 18, 19 ACE inhibitors have been demonstrated to reduce plasma levels of PAI-1, [20] [21] [22] [23] [24] whereas contrasting results have been reported on the effects of the angiotensin II (Ang II) antagonists. [22] [23] [24] [25] [26] [27] The aim of the present study was to evaluate the effects on plasma PAI-1 and t-PA activities of the combination of delapril, a nonsulphydryl, nonprolinic, lipophilic ACE inhibitor, with high affinity for the C-terminal site of ACE 28 with manidipine, a second-generation, lipophilic dihydropyridine Caantagonist, with good efficacy/tolerability profile 29 as compared to the combination of the Ang II AT1 receptor antagonists irbesartan with hydrochlorothiazide in the treatment of hypertensive patients with type II diabetes mellitus, a population with a great impairment of the fibrinolytic function.
Patients and methods
This randomized, double-blind, double-dummy, parallel group study included 80 outpatients 37 men and 43 women, aged 41-65 years, with mild-tomoderateessentialhypertension(diastolicBP,DBPX95 and p105 mmHg) and concomitant type II, noninsulin-dependent diabetes mellitus (National Diabetes Data Group criteria) 30 in stable metabolic control with diet and/or hypoglycaemic agents by at least 6 months (HbA1c o7.5% at three consecutive bimonthly controls). The baseline demographic and clinic characteristics are shown in Table 1 . Patients with secondary hypertension, smoking habits, obesity (BMIX30 kg/m 2 ), total cholesterol (TC) X5.2 mmol/l, renal failure (serum creatinine 4115 mmol/l), previous or active ischaemic heart disease, major noncardiovascular diseases and pregnancy were excluded from the study. The study protocol was approved by the local Ethical Committee and informed consent was obtained from each patient at the time of enrolment. After an initial 4-week run-in period with placebo, patients were randomly assigned to receive delapril 30 mg once the daily or irbesartan 150 mg once daily for 8 weeks. Thereafter, manidipine 10 mg once daily was added to delapril and hydrochlorothiazide 12.5 mg to irbesartan treatment for a further 8 weeks. Patients had to maintain the usual diet, and the same level of physical activity and body weight from the time of enrolment until the completion of the study. Oral antidiabetic therapy, when necessary, was maintained throughout the study and no other medication was allowed. BP, plasma t-PA and PAI-1 activities were evaluated at the end of the run-in (baseline value), after 4-week monotherapy treatments, and at the end of the combination treatment periods. BP was measured in the seated position with a standard mercury sphygmomanometer (Korotkoff I and V) using a cuff of appropriate size. Measurements were taken in the morning before daily drug intake (ie 24 h after dosing) and after 10 min rest in a quiet room. Three successive BP readings were obtained at 1-min intervals and averaged. Regarding fibrinolytic measurements, blood was always drawn before BP evaluation between 8:00 and 9:00 h after a 15-min rest and overnight fasting, to reduce interference with the diurnal variation of PAI-1 and t-PA. 31 Samples were collected in Biopool Stabilyte tubes with citrate buffer pH 4.5 to ensure the stability of t-PA activity 32 without affecting the assay of PAI-1 activity. 33 Plasma was separated within 1 h by centrifugation for 20 min at 3000 Â g and stored at À701C until assay. Plasma t-PA activity 34 was determined with a parabolic rate assay based on fibrin stimulation of the t-PA-catalysed conversion of Glu-plasminogen to plasmin, which subsequently cleaves the chromogenic substrate. The t-PA activity was expressed in IU/ml by reference to the World Health Organization First International Standard for t-PA coded 86/670 from the National Institute for Biological Standard and Control, Potters Bar, England. Plasma PAI-1 activity 35 was determined with a two-stage, indirect enzymatic assay based on the addition of excess t-PA (40 IU/ml) to the samples and measurement of the residual t-PA activity. One unit of PAI-1 activity was defined as the amount of PAI-1 that inhibits 1 IU of international t-PA standard. The reagent kits for assay of t-PA and PAI-1 activities were purchased from Biopool AB, Umea, Sweden. 
Data are expressed as means7standard deviations. The homogeneity of pretreatment values of PAI-1, t-PA and other metabolic and clinic parameters was evaluated by one-way analysis of variance (ANOVA). Within-group and betweengroup variations of BP and PAI-1 were compared using ANOVA for repeated measures. Spearman's rank test was used for correlation analysis between the changes in PAI-1 and t-PA activities and the reduction in BP values induced by various treatments. A value of Po0.05 was regarded as statistically significant.
It was calculated that a sample size of 40 evaluable patients per group was required in order to have an 80% probability of demonstrating a between-treatment difference of X10 IU/ml (s.d. ¼ 15) in PAI-1 activity with a significance of p5% (twotailed test).
Results
Of the 80 patients enrolled, 76 (39 in the delaprilmanidipine group, and 37 in the irbesartan-hydroclorothiazide group) completed the study. Two patients dropped out for adverse events (one for coughing during delapril monotherapy and one for headache during irbesartan monotherapy) and two patients were excluded because they did not show at study visits. As shown in Table 1 there were no significant differences in age, BMI, BP values, fasting glycaemia, HbA 1c , insulin, PAI-1 and t-PA activity between the two treatment groups at the end of the placebo period. The results of the study, which refer to the patients who completed the study, are shown in Table 2 . Both delapril and irbesartan significantly reduced systolic (SBP) and DBP and no difference in BP lowering efficacy was found either between the two monotherapies or between the two combination therapies. Delapril monotherapy significantly decreased plasma PAI-1 activity vs placebo (À10.4 IU/ml; Po0.05). The addition of manidipine produced a significant increase in t-PA activity ( þ 0.17 IU/ml; Po0.05), without significantly changing PAI-1 activity as compared to delapril monotherapy. Irbesartan monotherapy did not significantly affect either PAI-1 activity or t-PA activity. The addition of hydrochlorothiazide produced an increase in plasma PAI-1 activity vs placebo ( þ 9.5 IU/ml; Po0.05), with no significant effect on t-PA activity. As a consequence, at the end of the combination treatment period, PAI-1 activity was lower (15.677.5 vs 35.6717.4 IU/ml) and t-PA activity was higher (0.7870.33 vs 0.4070.19 IU/ml) in the patients treated with the delapril-manidipine combination as compared to those treated with irbesartan þ hydrochlorothiazide, the difference between treatments being statistically significant (Po0.01 for PAI-1 changes from baseline and Po0.05 for t-PA changes).
No significant correlation was found between the changes in PAI-1 and t-PA activities and the reduction in BP values obtained with various treatments.
There was no significant change in BMI, fasting blood glucose and plasma insulin during the study period. Glycaemic control, as assessed by HbA 1c , was not influenced by either treatment (Table 2) and no patients required changes in hypoglycaemic therapy.
Discussion
The results of this study indicate that in hypertensive patients with type II diabetes mellitus, the combinations delapril-manidipine and irbesartanhydrochlorothiazide are equally effective in reducing BP levels and significantly more effective than the monotherapy with delapril or irbesartan. This confirms that more intensive control of BP, which is needed to protect these high-risk patients from target organ damages, requires a combination therapy.
Although equally effective in reducing BP levels, the two combinations produced different effects on the fibrinolytic system. The delapril-manidipine combination improved the fibrinolytic balance, inducing a decrease in plasma PAI-1 activity and an increase in t-PA activity. These favourable results are probably due to the combined action of ACE inhibition, which has been demonstrated by most studies in the literature to reduce plasma PAI-1 levels [20] [21] [22] [23] [24] and the Ca-antagonist effect, which seems to enhance t-PA activity. 18, 19 In the present study, Effect of delapril-manidipine on fibrinolysis in hypertensive diabetics A Mugellini et al delapril alone significantly decreased PAI-1 activity. According to the literature, this effect might be due to: (a) the inhibition of Ang II formation: infusion of Ang II in normotensive volunteers and hypertensive subjects has been associated with a marked increase in plasma PAI-1 antigen, 36 and several in vitro studies using endothelial and vascular smooth muscle cells have demonstrated a stimulatory effect of Ang II on PAI-1 expression; 37 (b) the inhibition of kinin degradation with consequent increase in plasma levels of bradykinin, which stimulates t-PA production in animal models and in humans; 38 (c) the improvement in insulin sensitivity: insulin resistance and proinsulin, which are typically elevated in type II diabetic patients, contribute to increase PAI-1 activity 39 and ACE inhibitors have been shown to reduce insulin resistance. 40 The addition of manidipine produced a significant increase in t-PA activity in this study, which is consistent with previous observations. 18, 19 The mechanisms of this increase in t-PA activity are not clear, but it might be due to a direct action of calcium channel blockade on vascular endothelium.
On the contrary, the irbesartan-hydrochlorothiazide combination worsened the fibrinolytic system balance, inducing an increase in PAI-1 activity. In this study irbesartan monotherapy did not significantly affect the fibrinolytic balance, thus confirming previous findings. [22] [23] [24] [25] [26] [27] Possible explanations for the dissimilar effect of ACE inhibition and Ang II antagonism on PAI-1 levels might be that: (a) the endothelial receptors that mediate PAI-1 expression in response to Ang II are not type I receptor subtypes, but rather the AT4 receptors, which specifically bind to the hexapeptide 3-8 fragment of Ang II, indicated as Ang IV; 41 (b) unlike ACE Inhibitors, Ang II antagonists have no effect on the endogenous kinins. 42 The addition of hydrochlorothiazide to irbesartan monotherapy produced a significant increase in PAI-1 activity, which confirms previous observations. 18 The mechanism of this unfavourable effect of hydrochlorothiazide needs to be clarified.
The different effects of various treatments on the fibrinolytic balance observed in this study cannot be explained by a difference in BP lowering as no significant correlation was found between the changes in PAI-1 and t-PA activities and the reduction in BP values.
One possible limitation of the present study may be the lack of a placebo group, which does not allow us to exclude the possibility that some changes in the fibrinolytic balance were a function of time or other factors. Since a close relationship exists between plasma lipids and fibrinolytic parameters, 43 changes in lipid profile might partly account for modifications in the fibrinolytic balance. In the present study, including patients with normal cholesterol levels and avoiding changes in diet and body weight would have limited such possible interaction; however, the lack of data about the lipid pattern throughout the study does not allow us to further discuss this point.
In conclusion, the results of the present study, which refer to hypertensive type II diabetic patients, a population with an impaired fibrinolysis, suggest that in these patients the delapril-manidipine combination may determine a better improvement of the fibrinolytic balance than the single drugs given in monotherapy, while the irbesartan-hydrochlorothiazide combination seems to worsen it. This finding represents a further support to the use of the combination of an ACE inhibitor with a Ca-antagonist in these high-risk patients, where it is difficult to reach the required BP goal with monotherapy alone. However, whether or not in the clinical setting the observed changes in PAI-1 and t-PA activities may result in a different degree of cardiovascular protection remains to be clarified.
